Adenosine Phosphate
CAS 61-19-8
Adenosine Phosphate (CAS 61-19-8) is a Phase 4 pharmaceutical compound with 10 bioactivity targets and 7 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 28974.523999999998 nM | 75 | - |
| - | IC50 | 27227.134074074074 nM | 26 | - |
| - | EC50 | 31482.7 nM | 17 | - |
| - | Kd | 520431.9209090909 nM | 11 | - |
| - | Potency | 17580.1 nM | 8 | - |
| - | Ki | 1079533.3716666668 nM | 6 | - |
| Fructose-1,6-bisphosphatase 1 Enzyme |
IC50 | 6.85 | - | Homo sapiens |
| Fructose-1,6-bisphosphatase 1 Enzyme |
IC50 | 5.89 | - | Sus scrofa |
| Proto-oncogene tyrosine-protein kinase Src Kinase |
IC50 | 7 | - | Homo sapiens |
| Transient receptor potential cation channel subfamily M member 2 Ion channel |
IC50 | 4.15 | - | Homo sapiens |
| Transient receptor potential cation channel subfamily M member 4 Ion channel |
IC50 | 4.7 | - | Homo sapiens |
| Pol polyprotein Enzyme |
Ki | 9.64 | - | Human immunodeficiency virus 1 |
| Alcohol dehydrogenase Enzyme |
Ki | 4.42 | - | Equus caballus |
| L-lactate dehydrogenase A chain Enzyme |
Kd | 3.19 | - | Homo sapiens |
| Ketopantoate reductase Enzyme |
Ki | 2.2 | - | Escherichia coli (strain K12) |
| Adenylate kinase 2 Kinase |
Ki | 4.1 | - | Rattus norvegicus |
| 2'-deoxynucleoside 5'-phosphate N-hydrolase 1 Enzyme |
Ki | 4.72 | - | Homo sapiens |
| 2'-deoxynucleoside 5'-phosphate N-hydrolase 1 Enzyme |
Ki | 4.4 | - | Rattus norvegicus |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Drug hypersensitivity | 12 | 58.761 | 10013700 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| AMP kinase | Activation | 4.210000038146973 pEC50 | 16753576 |
| TRPM4 TRPM4 |
Antagonist | 4.7 pIC50 | 14758478 |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| ADENOSINE PHOSPHATE | 309 | SU | MTHSPL |
| adenosine monophosphate | 309 | PIN | RXNORM |
| adenosine 5'-monophosphate | 309 | SY | RXNORM |
| 5'-adenylic acid | 309 | SY | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Adenosine Phosphate used for in pharmaceutical contexts?
Adenosine Phosphate (CAS 61-19-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Adenosine Phosphate?
Adenosine Phosphate has 7 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Drug hypersensitivity, Drug ineffective for unapproved indication, Off label use. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Adenosine Phosphate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Adenosine Phosphate with EU status "permitted".
What clinical phase is Adenosine Phosphate in?
Adenosine Phosphate is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Adenosine Phosphate?
Adenosine Phosphate has 18 bioactivity rows in this page query. Rendered target entries include Fructose-1,6-bisphosphatase 1, Proto-oncogene tyrosine-protein kinase Src, Transient receptor potential cation channel subfamily M member 2, Transient receptor potential cation channel subfamily M member 4, Pol polyprotein.